Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Raw Materials (2023 - 2025)

Krystal Biotech's Raw Materials history spans 3 years, with the latest figure at $15.9 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 16.86% year-over-year to $15.9 million; the TTM value through Dec 2025 reached $15.9 million, up 16.86%, while the annual FY2025 figure was $15.9 million, 16.86% up from the prior year.
  • Raw Materials for Q4 2025 was $15.9 million at Krystal Biotech, up from $14.6 million in the prior quarter.
  • Across five years, Raw Materials topped out at $15.9 million in Q4 2025 and bottomed at $3.2 million in Q4 2023.
  • The 3-year median for Raw Materials is $13.6 million (2024), against an average of $10.6 million.
  • The largest annual shift saw Raw Materials surged 332.44% in 2024 before it rose 16.86% in 2025.
  • A 3-year view of Raw Materials shows it stood at $3.2 million in 2023, then soared by 332.44% to $13.6 million in 2024, then grew by 16.86% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Raw Materials are $15.9 million (Q4 2025), $14.6 million (Q3 2025), and $14.1 million (Q2 2025).